Literature DB >> 21911461

Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines.

Matthew J Burton1, Athumani Ramadhani, Helen A Weiss, Victor Hu, Patrick Massae, Sarah E Burr, Wahida Shangali, Martin J Holland, David C W Mabey, Robin L Bailey.   

Abstract

The immunological basis of scarring trachoma is not well understood. It is unclear whether it is driven primarily through cell-mediated adaptive or epithelial-cell-derived innate responses. The purpose of this study was to investigate the expression of the inflammatory and fibrogenic mediators which may be involved. We conducted a cross-sectional survey of children living in an untreated trachoma-endemic community in Tanzania. The children were examined for signs of trachoma, and swabs were collected for bacteriological culture and RNA and DNA isolation. Chlamydia trachomatis was detected by the Amplicor PCR test. The expression of the following genes was measured by quantitative reverse transcription-PCR (RT-PCR): S100A7, IL1B, IL17A, IL23A, CXCL5, CCL18, TLR2, NLRP3, KLRD1, CTGF, and MMP9. Four hundred seventy children under the age of 10 years were included. Follicular trachoma (TF) was detected in 65 children (14%), C. trachomatis was detected in 25 (5%), and bacterial pathogens were cultured in 161 (34%). TF was associated with significantly increased expression of S100A7, IL17A, CCL18, CXCL5, and CTGF. Expression was increased further in the presence of papillary inflammation. Nonchlamydial bacterial infection was associated with increased expression of IL17A, CXCL5, CCL18, and KLRD1. IL17A expression was associated with increased expression of S100A7, CXCL5, CCL18, KLRD1, and CTGF. These data are consistent with a role for IL-17A in orchestrating the proinflammatory response in trachoma. Its activity may be promoted either as part of the cell-mediated response or through innate pathways. It may drive a range of proinflammatory factors leading to excessive tissue damage and repair involving fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911461      PMCID: PMC3232643          DOI: 10.1128/IAI.05718-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  62 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.

Authors:  Stefan Prokop; Frank L Heppner; Hans H Goebel; Werner Stenzel
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting.

Authors:  Matthew J Burton; Victor H Hu; Patrick Massae; Sarah E Burr; Caroline Chevallier; Isaac A Afwamba; Paul Courtright; Helen A Weiss; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

4.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

5.  Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines.

Authors:  K H Ramsey; R G Rank
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  A CXCL5- and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells.

Authors:  April E Nedeau; Richard J Bauer; Katherine Gallagher; Haiying Chen; Zhao-Jun Liu; Omaida C Velazquez
Journal:  Exp Cell Res       Date:  2008-04-25       Impact factor: 3.905

7.  Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls.

Authors:  R L Bailey; M J Holland; H C Whittle; D C Mabey
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

8.  Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli.

Authors:  Arby Abtin; Leopold Eckhart; Michael Mildner; Florian Gruber; Jens-Michael Schröder; Erwin Tschachler
Journal:  FASEB J       Date:  2008-02-08       Impact factor: 5.191

9.  The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes.

Authors:  Matthias Michalek; Christoph Gelhaus; Oliver Hecht; Rainer Podschun; Jens Michael Schröder; Matthias Leippe; Joachim Grötzinger
Journal:  Dev Comp Immunol       Date:  2009-01-20       Impact factor: 3.636

Review 10.  CTGF and chronic kidney fibrosis.

Authors:  Xin-Ming Chen; Weier Qi; Carol A Pollock
Journal:  Front Biosci (Schol Ed)       Date:  2009-06-01
View more
  24 in total

Review 1.  Trachoma: an update on prevention, diagnosis, and treatment.

Authors:  Satasuk Joy Bhosai; Robin L Bailey; Bruce D Gaynor; Thomas M Lietman
Journal:  Curr Opin Ophthalmol       Date:  2012-07       Impact factor: 3.761

Review 2.  Trachoma and Ocular Chlamydial Infection in the Era of Genomics.

Authors:  Tamsyn Derrick; Chrissy h Roberts; Anna R Last; Sarah E Burr; Martin J Holland
Journal:  Mediators Inflamm       Date:  2015-09-03       Impact factor: 4.711

3.  Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies.

Authors:  Matthew J Burton; Saul N Rajak; Victor H Hu; Athumani Ramadhani; Esmael Habtamu; Patrick Massae; Zerihun Tadesse; Kelly Callahan; Paul M Emerson; Peng T Khaw; David Jeffries; David C W Mabey; Robin L Bailey; Helen A Weiss; Martin J Holland
Journal:  PLoS Negl Trop Dis       Date:  2015-05-13

Review 4.  Towards a safe and effective chlamydial vaccine: lessons from the eye.

Authors:  David C W Mabey; Victor Hu; Robin L Bailey; Matthew J Burton; Martin J Holland
Journal:  Vaccine       Date:  2014-03-20       Impact factor: 3.641

Review 5.  Insights Into Host Cell Cytokines in Chlamydia Infection.

Authors:  Wenjing Xiang; Nanyan Yu; Aihua Lei; Xiaofang Li; Shui Tan; Lijun Huang; Zhou Zhou
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

6.  KLRD1, FOSL2 and LILRB3 as potential biomarkers for plaques progression in acute myocardial infarction and stable coronary artery disease.

Authors:  Qiang Zhang; Yue Zheng; Meng Ning; Tong Li
Journal:  BMC Cardiovasc Disord       Date:  2021-07-16       Impact factor: 2.298

7.  Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections.

Authors:  Chrissy H Roberts; Anna Last; Sandra Molina-Gonzalez; Eunice Cassama; Robert Butcher; Meno Nabicassa; Elizabeth McCarthy; Sarah E Burr; David C Mabey; Robin L Bailey; Martin J Holland
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

Review 8.  Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis.

Authors:  Victor H Hu; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2013-02-14

9.  Post-operative recurrent trachomatous trichiasis is associated with increased conjunctival expression of S100A7 (psoriasin).

Authors:  Matthew J Burton; Saul N Rajak; Athumani Ramadhani; Helen A Weiss; Esmael Habtamu; Bayeh Abera; Baye Abera; Paul M Emerson; Peng T Khaw; David C W Mabey; Martin J Holland; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20

10.  Conjunctival MicroRNA expression in inflammatory trachomatous scarring.

Authors:  Tamsyn Derrick; Chrissy h Roberts; Megha Rajasekhar; Sarah E Burr; Hassan Joof; Pateh Makalo; Robin L Bailey; David C W Mabey; Matthew J Burton; Martin J Holland
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.